Will PP405 be prohibitively expensive or will it be roughly the same as fin or min?
    Research/Science 8/30/2025

    From the encyclopedia
    PP405 →

    mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    At a glance
    In this general discussion post the tone is 😐 neutral.

    Other terms

    PP405 is expected to be more expensive than finasteride and minoxidil initially due to patent protection, but not as costly as life-saving medications like Ozempic. The price may decrease after the patent expires, but initially, it might be around $100 per month, making it potentially unaffordable for many.
    View this post in the Community →

    Similar Community Posts Join

    6 / 6 results

      community Won’t pp405 and gt20029 be patented and be almost unreasonably expensive

       29 upvotes 1 year ago
      Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

      community The expected timeline for PP405 - Next update at AAD Annual Meeting in March 2026 ?

       34 upvotes 8 months ago
      A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

      community What is the ultimate hair regrowth protocol

       29 upvotes 1 year ago
      The conversation covers aggressive hair regrowth treatments like Dutasteride, Minoxidil (oral and topical), RU58841, microneedling, and ketoconazole shampoo. It also mentions PRP, laser therapy, GHK-Cu injections, and hormone therapy for maximum regrowth.

    Related Research

    6 / 6 results
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
      Recent Advances in Drug Development for Hair Loss

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
      PP405 in Alopecia: An Emerging Molecule Worth Investigating

      research PP405 in Alopecia: An Emerging Molecule worth Investigating

      January 2026 in “Journal of Community Medicine and Health Solutions”
      In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.
      Diagnostic Comparison: SH-1 Molecule vs PP405 — Safety Profiles in Hair Science

      research Diagnostic Comparison: SH‑1 Molecule vs PP405 — Safety Profiles in Hair Science

      June 2026 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This infographic compares the safety profiles of SH‑1, a cosmetic ingredient, which showed no systemic absorption, and PP405, an investigational drug with dose-dependent systemic uptake and potential threshold breaches, highlighting differences in safety between cosmetic and investigational substances according to this report.